Technology ID
TAB-3714

Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS)

E-Numbers
E-009-2019-0
Lead Inventor
Sati, Pascal (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Reich, Daniel (National Institute of Neurological Disorders and Stroke)
Patil, Sunil (Siemens Medical Solutions USA)
Applications
Software / Apps
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Neurology
Infectious Disease
Endocrinology
Dental
Cardiology
Research Products
Research Equipment
Computational models/software
Lead IC
NINDS
This technology includes an automated and non-invasive assessment system called Automated Identification of subjects at risks of Multiple Sclerosis (AIMS) to assist clinicians in their diagnostic evaluation. A focus of AIMS is the ‘central vein sign’ (and other radiological findings). The methodology is composed of the following features:
  1. Ultra-fast high-resolution susceptibility imaging of the brain using novel MRI technique called 3D segmented echo-planar-imaging
  2. Novel MRI contrasts (e.g., FLAIR*, QSM) using advanced processing
  3. Fully automated detection for brain lesions, central vein sign and lesion rims, using novel statistical/machine-learning techniques
AIMS will ultimately generate a report describing all the information obtained from the image analysis and will classify the patients as either a low risk or high risk for MS.
Commercial Applications
There are no commercially-available tools for automatically detecting central veins in cerebral plaques and assisting clinicians in the diagnosis of MS using radiological findings.

Competitive Advantages
AIMS is the first non-invasive automated assessment of the ‘central vein sign’ (small veins inside lesions) in patient brains.

Request More Info

Licensing Contact:
Sharma, Smita
smita.sharma@nih.gov

Patents

Publications

Date Published